Exploring Outcomes and Characteristics of Myasthenia Gravis 2

(EXPLORE-MG2 Trial)

Recruiting at 9 trial locations

Overseen By Helen Girma

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Yale University

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

400 Participants Needed

Trial Summary

What is the purpose of this trial?

The goal of this prospective observational study is to create a network repository of clinical data and biological samples to help researchers learn more about myasthenia gravis.

Research Team

Vern Juel, MD

Principal Investigator

Duke University

Richard Nowak, MD

Principal Investigator

Yale University

Eligibility Criteria

Inclusion Criteria

You have the cognitive aptitude to comprehend and consent to a legal document.

You have been diagnosed with Myasthenia Gravis based on clinical presentation, seropositivity for MG-associated autoantibodies, and/or a decremental response to repetitive nerve stimulation, positive single fiber EMG or edrophonium test; and the signs and symptoms cannot be explained by any other disease process.

You must be amenable to finishing the study and attending subsequent appointments.

Treatment Details

Participant Groups

Group I: Neurological Outpatients Experimental Treatment 1 Intervention

Participants in this group will be recruited from the outpatient clinical population at MGNet participating sites. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

National Center for Advancing Translational Sciences (NCATS)

Collaborator

Trials

394

Recruited

404,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials

1,403

Recruited

655,000+